

Towards precision oncology with patient-derived xenografts

Eugenia R. Zanella^{1,3}, Elena Grassi^{1,2,3} and Livio Trusolino^{1,2}

¹Candiolo Cancer Institute – FPO IRCCS, 10060 Candiolo, Torino, Italy

²Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy

³These authors contributed equally: Eugenia R. Zanella, Elena Grassi

Correspondence: livio.trusolino@ircc.it

Under drug pressure, tumours dynamically evolve multiple adaptive mechanisms that make static interrogation of genomic alterations insufficient to inform treatment decisions. Research in humans does not allow analyzing how the various tumour's regulatory circuitries are affected by therapeutic insults over time and space. Likewise, testing different precision treatments based on composite and ever-changing molecular information is hard to achieve in patients. Preclinical models are therefore needed that incorporate the biology and genetics of human cancers, navigate complex variables, and enable adequate population throughput for pinpointing randomly distributed response predictors. Patient-derived tumour xenografts (PDXs) represent dynamic entities in which cancer evolution can be monitored through serial propagation in mice. PDXs also reflect inter-patient diversity, thus enabling the nomination of response biomarkers and therapeutic targets for molecularly circumscribed tumour subgroups. Here, we discuss recent examples of the use of PDXs to tackle the continuum of precision oncology, from translational research to clinically oriented drug discovery. We elaborate on how and to what extent preclinical observations in PDXs have confirmed in some cases, and anticipated in others, findings in patients. Finally, we illustrate emerging methodological efforts that may broaden the application of PDXs by honing their predictive accuracy or by improving their versatility.

The characterization of cancer genomes has provided a catalogue of oncogenic mutations across tumours and ignited the development of therapeutic strategies tailored around individual, tumour-specific genetic aberrations with clinical actionability^{1,2}. However, several issues complicate the routine implementation of therapies based on tumour genotyping. First, the response of tumours to targeted therapy may transcend their genomes³. For example, inhibiting the product of a single dominant oncogene could trigger compensatory signalling feedbacks, switches in cancer cell plasticity and deviations in evolutionary trajectories, all leading to the acquisition of new dependencies that substitute for those sustained by the inhibited target^{4,5}. Because of this complexity, not always is tumour genomic profiling sufficient to inform therapeutic decisions and predict treatment outcome, and in many cases a *bona fide* oncogenic driver proves not to be a viable therapeutic target⁶. Second, while some genetic aberrations occur at high frequency in specific cancer types, many tumours exhibit a "long tail" distribution of rare alterations that are difficult to recognize in modestly sized patient cohorts, and are hard to qualify as driver genes rather than random passenger mutations⁷.

The above considerations adduce arguments to what we believe is the essence of precision oncology: the distillation of co-dependencies and connectivities that attenuate response to targeted therapies in genetically defined contexts and the identification of combinatorial ways to tame such collateral liabilities pharmacologically. For precision oncology to manifest its full potential, platforms and data sets are needed that extend tumour molecular diversity to the extreme of reaching as much

saturation as possible. By enabling genomic profiling, biological annotation and therapeutic investigation in a multiverse of virtually unlimited patient tumour samples, PDXs have been demonstrated to be powerful tools to pursue the inventory and experimental interrogation of cancer genes and to test their value as drug targets. Here we illustrate the tapestry of functional and clinical insights that have recently emerged from PDX-based research and how studies in the field have contributed to illuminating various angles of precision oncology.

Tumour heterogeneity and evolution

In solid tumours, cancer cells are embedded in a supportive microenvironment made of stromal cells – such as fibroblasts and endothelial cells – and innate and adaptive immune cells⁸. Moreover, cancer cells are a constellation of distinct subpopulations with different phenotypic traits and genetic make-ups that are constantly moulded by time, spontaneous attrition dynamics, and therapeutic pressure⁹. Because of the variegated nature of tumour cell composition and the heterogeneous intra-tumour distribution of genetic alterations, the establishment of a PDX implies a concatenation of random events (Figure 1): (1) tumour sub-sampling for production of implantable tissue fragments introduces a certain degree of geographical bias; (2) once injected in the mouse, only a fraction of cancer cells are competent to engraft, which reduces genetic diversity due to out-competition by the fittest and most rapidly proliferating clone(s); (3) serial PDX propagation can further exacerbate PDX divergence owing to mutational evolution and phenotypic adaptation over time and space.

These peculiarities may be deemed as limitations of the methodology when pondering the accuracy of PDX models in fully phenocopying tumours of the donor patients. However, the analysis of tumour molecular deviation through repeated passages in mice has provided considerable insight into the rules that govern cancer evolutionary trajectories, clonal competition and non-genetic adaptation¹⁰. Likewise, the assessment of the dynamic impact of treatment on PDXs' clonal architecture and transcriptional features has advanced our understanding of the mechanisms underlying drug resistance¹¹.

Preservation of genetic identity

A lively debate is ongoing whether the architecture of copy number alterations (CNAs) evolves or remains stable throughout PDX propagation in mice. Ben David and colleagues used gene expression microarray data to infer CNA profiles in more than 500 PDX models across 24 cancer types¹². This analysis revealed that approximately 60% of the models acquired at least 1 large chromosomal abnormality within a single passage, a frequency that increased to 90% when analyzing tumours from the first 4 passages¹². As expected for a founder effect whereby model initiation imposes a strong selection pressure, genomic diversity was more evident in first- and early-passage xenografts than in xenografts at later passages.

A joint initiative of the National Cancer Institute PDXNet consortium and the EurOPDX consortium, involving a collection of more than 1,400 samples corresponding to 509 PDX models across 16 tumour types, questioned the assumption that PDXs show copy number divergence from their tumours of origin¹³. The controversy mainly stemmed from technical issues, specifically from the consideration that expression-based CNA calling has lower segmental resolution than DNA-based methods, allowing for CNA enumeration only at the scale of entire chromosomal arms. Moreover, microarray intensities of cancer cells are diluted by human stromal cells in bulk pre-implantation tumours but not in PDXs, which results in variability in the expression signals that can be erroneously interpreted as copy number changes. Copy number estimation by DNA-based measurements did not confirm mouse-induced copy number evolution and did not reveal positive selection of cancer-related genes in CNAs from PDXs compared with matched patient tumours¹³. Notably, CNA variations between original and mouse-passaged tumours were comparable to differences in multi-region tumour samples or intra-patient-samples, suggesting that PDX-associated genetic drift is more influenced by spatial heterogeneity than genetic instability.

A preliminary consensus across studies is emerging, whereby approximately 90% of the genome appears to be concordant between PDXs and original tumours. According to a reassessment of the PDXNet and EurOPDX dataset by Ben David and colleagues, a median of 10% of the genome was differentially affected by copy number variations in matched tumours and PDXs¹⁴. Similarly, in another collection of 536 samples across 25 cancer types, a 10% divergence between PDXs and their corresponding parental tumours was reported at the level of single-nucleotide alterations for key driver genes, along with occasional examples of PDX-associated CNA evolution that consolidated along serial passages¹⁵. Whether these differences, in a context of general concordance, are to be considered relevant, remains a matter of opinion.

Clinical considerations

Even in the best scenario of a high degree of molecular fidelity between PDXs and original tumours, the bottlenecks associated with model derivation and propagation, coupled with the inherent genomic instability of cancer, inevitably introduce some extent of genetic deviation. This may not affect the dominant prevalence of trunk (clonal) mutations, which are expected to be equally represented in original and propagated tumours. However, the pattern of branch (subclonal) mutations is likely to be different in passaged versus pre-implantation samples due to neutral evolution as well as selective pressure. Evidence continues to emerge that most cancers contain a minority of cells displaying innate resistance to drugs due to subclonal mutations¹⁶, so response to therapy may be different in PDXs compared to matched original tumours.

These caveats notwithstanding, potential genomic evolution does not seem to critically affect the accuracy of therapeutic response prediction in parental tumours and derived PDXs. A retrospective

analysis of clinical outcome compared with response to the same treatment in the corresponding PDX in 92 patients with advanced solid tumours revealed a sensitivity of 96% and a specificity of 70% for the PDX drug screens, resulting in positive and negative predictive values of 85% and 91%, respectively¹⁷. In principle, these results bode well for the execution of prospective co-clinical trials that exploit PDXs as “avatars” for drug efficacy studies, with the aim to pass pharmacological information back to the donor patient for direct therapeutic intervention. Although initial efforts in this direction have been successfully attempted for pancreatic cancer¹⁸, the value of PDX models as predictive tools for real-time clinical decision making is limited by the laboriousness of PDX-based experimentation, which hardly aligns to the relatively quick timescales of clinical practice.

Dynamics of genomic clones

PDX engraftment and expansion are accompanied by changes in the clonal organization of tumours. This divergence makes PDXs versatile models to trace the intra-tumour architecture of genomic diversity and to correlate clonal competition with fitness effects, which is instrumental to parsing the principles of drug resistance in heterogenous cancer cell populations (Figure 1).

Breast cancer and colorectal cancer (CRC) are the tumour settings in which more mature knowledge has been garnered. In a seminal study, genomic clonal analysis of 15 breast cancer PDXs at single-cell resolution indicated strong variability in the patterns of initial clonal selection, ranging from moderate reshaping of clonal prevalence to extreme selective engraftment (and subsequent dominance) of minor subclones representing only a small fraction of the original population¹⁹. Over serial passaging, the spectrum of clonal expansions and declines was wider for tumours experiencing weak initial selection than for tumours characterized by massive early counterselection. Notably, parallel clonal dynamics were observed when cell populations from the same tumour were transplanted in multiple mice, with reproducible outgrowth of initially minor subclones¹⁹. This suggests that, in the models tested, directional clonal dynamics over time were not ascribable to stochastic processes (such as random genetic drift) but were deterministically associated with favourable mutational landscapes that conferred a predictable fitness advantage. More recently, Salehi and colleagues performed time-series fitness mapping experiments in three triple-negative breast cancer (TNBC) PDXs using single-cell CNAs as heritable genotypes to trace clonal trajectories over the course of standard-of-care chemotherapy²⁰. They found that prolonged treatment with cisplatin, until development of resistance, suppressed high-fitness clones that had dominated in the absence of therapy; conversely, chemotherapy selected for phylogenetic lineages initially endowed with low fitness²⁰.

Engraftment-related subclonal skewing has also been documented in CRC PDXs. In four of nine tumours analyzed, dominant parental clones were less represented and minor parental subclones became dominant in PDXs compared with original tumours, with a general reduction of clonal

heterogeneity and a decreased prevalence of regionally confined subclonal mutations²¹. Kreso and colleagues monitored spontaneous and drug-induced evolutionary dynamics by combining CNA analysis and deep sequencing of mutational hotspots with lentiviral lineage tracing in 10 PDX models. After the usual clonal selection during engraftment, tumours remained genetically stable in subsequent passages²². However, when genetically homogeneous clones were marked with lentiviral vectors to track the progeny of single CRC cells, the ensuing lineages showed marked functional heterogeneity, with idiosyncratic variabilities in growth rates, tendency to persist, or propensity to decline in the face of a shared genetic ancestry²². In coherence with the fitness mapping conducted in breast cancer²⁰, treatment of mice bearing CRC PDXs with oxaliplatin preferentially eliminated persistent, high-fitness progeny and increased the proportion of previously dormant lineages²². However, different from breast cancer, variations in fitness landscape under drug pressure were not dictated by clonal selection of heritable genomic traits; rather, fitness was shaped by non-genetic mechanisms impacting on cell phenotypes.

Clinical considerations

The finding that cancer cell subpopulations poised to become chemorefractory showed reduced competitive ability in the absence of therapy^{20,22} indicates that drug resistance has an evolutionary fitness cost, which, in principle, could be enhanced by therapeutic intervention. Intriguingly, the biological characteristics of low-fitness clones in breast cancer PDXs and of dormant lineages in CRC PDXs echo those of slow-growing persisters, which have been repeatedly identified in cell cultures after prolonged treatment with kinase inhibitors^{23,24,25}. These persister cells display consistent hallmarks such as an altered chromatin organization²³, diminished apoptotic thresholds²⁴, and a metabolic shift to fatty acid oxidation²⁵. Targeting such hallmarks – for example with histone deacetylase (HDAC) inhibitors to modulate chromatin state, BH3 mimetics to precipitate apoptosis, and blockers of fatty acid catabolism to counteract metabolic adaptation – reduced the fraction of persisters in cell-based experiments^{23,24,25}.

Clinical information for patients treated with analogous approaches is, at present, fragmentary. Twenty-one of 38 individuals (55%) with chemorefractory metastatic CRC treated with a combination of the HDAC inhibitor vorinostat and the antimetabolite chemotherapeutic regimen 5-fluorouracil (5-FU)/leucovorin experienced disease stabilization, and one had a partial response²⁶. In contrast, the addition of the HDAC inhibitor chidamide did not improve the efficacy of cisplatin in the first-line treatment of 15 patients with advanced TNBC²⁷. Phase I studies of the BCL-2/BCL-XL inhibitor navitoclax in combination with gemcitabine or carboplatin/paclitaxel in patients with solid tumours showed modest but appreciable clinical efficacy (54% and 36.8% stable disease, respectively), which was associated with relatively high toxicity^{28,29}. Although clinical findings are still immature, therapies

aimed to further reduce the already limited fitness of prospectively resistant clones in heterogeneous tumours are expected to delay disease recurrence in patients.

Adaptive drug tolerance

The inherent genomic instability of tumours favours the stochastic acquisition of new mutations, some of which will afford cancer cells with a selective advantage to evade therapeutic pressure; the larger the pool of residual cells left behind by treatment, the higher the probability that a drug-resistant clone will emerge. Lingering cells that withstand therapy usually do so by implementing non-genetic mechanisms of drug tolerance, which entails various modalities of phenotypic adaptation⁵.

Recent evidence in PDX models has documented the importance of cellular plasticity in shaping drug response, in particular for melanoma and CRC. A common theme stemmed from PDX studies is that drug-tolerant residual cells often morph into tissue lineages that are reminiscent of those that compose normal organs or their embryonic ancestors. Single-cell RNA sequencing of *BRAF*-mutant melanoma PDXs at the zenith of maximal response to BRAF and MEK (MAPK) inhibition revealed the co-existence of distinct transcriptional states, one of which exhibited high expression of neural crest stem cell markers (melanocytes, from which melanoma arises, differentiate from neural crest progenitors during embryonic development)³⁰. This transition was induced by a gene regulatory network upstream controlled by retinoic X receptor- γ and culminating into the activation of an autocrine loop in which glial cell line-derived neurotrophic factor stimulated FAK signalling^{30,31} (Figure 2). Residual melanoma cells that survived MAPK blockade also displayed increased mitochondrial translation, which could be targeted by antibiotics that induce mitochondrial proteotoxic stress such as doxycyclin³².

In the absence of EGFR signalling, actively dividing stem cells of the normal mouse intestine convert into quiescent cells that are similar to a subpopulation of slowly cycling secretory precursors committed to differentiate into Paneth cells³³⁻³⁵. Likewise, cancer cells of metastatic CRC PDXs that persisted after prolonged treatment with the clinically approved EGFR antibody cetuximab displayed signs of secretory commitment and Paneth cell-like pseudodifferentiation³⁶, indicating analogies between the phenotypic reprogramming that fuels quiescence in the mouse normal intestine and that occurring during manifestation of drug tolerance in human colorectal tumours (Figure 2). The lineage switch toward the secretory/Paneth cell-like fate was accompanied by a signalling shift from high EGFR pathway activity to high HER2/HER3 activity³⁶.

The notion that drug tolerance in CRC entails the co-option of conserved lineages or developmental pathways is supported by additional findings. In residual PDXs long exposed to standard-of-care chemotherapy (5-FU and irinotecan), clonal heterogeneity and barcode complexity were maintained³⁷, in line with the observation by Kreso and colleagues that CRC cells are genetically equipotent in coping with therapeutic insults²². Instead, lingering cells entered a reversible state that

was evocative of diapause, a period of suspended development that delays blastocyst implantation in several mammalian species³⁸. Similar to diapaused blastocysts³⁹, residual CRC PDXs featured suppression of the mTOR pathway and upregulation of key autophagy genes³⁷ (Figure 2). Interestingly, a molecular adaptation resembling that of embryonic diapause has also been documented in breast and prostate cancer cells that tolerated treatment with several cytotoxic drugs⁴⁰, attesting to the generalizability of this evolutionarily conserved strategy in tumours that survive stressful conditions.

Clinical considerations

The drug-tolerant phenotypes described in residual PDXs – namely, the presence of neural crest stem cell markers in MAPK-inhibited melanomas, the Paneth cell-like transition induced by cetuximab in metastatic CRC and the diapause state experienced by CRC models exposed to chemotherapy – were verified in on-treatment biopsies from patients^{30,36,37}, thus confirming the reliability of PDXs in recapitulating clinical evidence. In melanoma, ongoing clinical experimentation has been inspired by the observation that FAK inhibition potentiates the anticancer effect of MAPK inactivation in residual PDXs with a neural crest stem cell phenotype³¹. In a phase Ib trial, the FAK inhibitor IN10018 is being tested together with the MEK inhibitor cobimetinib in subjects with metastatic uveal melanoma and *NRAS*-mutant metastatic melanoma (NCT04109456)⁴¹; similarly, a phase II trial is investigating the potential efficacy of combining the FAK inhibitor defactinib and the dual RAF/MEK inhibitor VS-6766 in patients with metastatic uveal melanoma (NCT04720417)⁴². No results are yet available for either study. Intriguingly, administration of doxycycline in a patient with metastatic melanoma under BRAF-MEK inhibitor therapy was accompanied by sudden regression of a gallbladder lesion, in line with the finding that enhanced mitochondrial translation (which is disrupted by doxycycline) counteracts the growth-inhibitory effect of MAPK blockade in melanoma PDXs³².

As mentioned above, HER2 and HER3 signalling is adaptively upregulated in residual PDXs of metastatic CRC that persist after cetuximab treatment³⁶, so inhibition of HER2 and/or HER3 along with EGFR is expected to be more effective than inhibition of EGFR alone in increasing the depth of response and prolonging survival in patients. In a phase I trial in which cetuximab was administered together with the dual EGFR/HER2 inhibitor lapatinib in 6 patients with metastatic CRC, marked clinical activity was noted, with a disease control rate of 83% (33% objective response and 50% stable disease)⁴³. Conversely, a phase II randomized study in 134 patients treated with 5-FU and irinotecan reported that the addition of the dual EGFR/HER3 antibody duligotuzumab provided no advantage in progression-free survival (PFS) or overall survival (OS) compared with the addition of the single-target EGFR antibody cetuximab⁴⁴. In this case, results may have been biased by the potentially uneven effect of the chemotherapy backbone, which was reduced to lower dose intensity in the duligotuzumab arm owing to a higher frequency of gastrointestinal toxicity.

Anecdotal evidence suggests that inhibitors of autophagy – a functional hallmark of diapause – may be beneficial when combined with other drugs in CRC. In a phase I trial, the combination of the anti-autophagy compound hydroxychloroquine and the HDAC inhibitor vorinostat induced partial response or stable disease lasting more than two cycles in 5 of 12 CRC patients (42%)⁴⁵. A case report of a subject with a *KRAS* mutant metastatic sigmoid adenocarcinoma documented improvement of the performance status and a reduction in the size of lung metastases soon after the concomitant administration of the MEK inhibitor binimetinib, the anti-angiogenic antibody bevacizumab and hydroxychloroquine⁴⁶. However, in both instances the specific contribution of hydroxychloroquine within the therapeutic cocktails could not be discerned, and whether inhibitors of autophagy improve the outcome of chemotherapy in CRC patients remains to be elucidated.

Tumour composition

After tumour engraftment, the human stroma is quickly replaced by murine stroma. Therefore, the PDX transcriptome is an amalgam of human RNAs (originating from cancer cells) and mouse RNAs (originating from stromal cells). The chimeric composition of PDXs has been leveraged to deconvolute cancer cell versus stromal signals in bulk xenografts by employing bioinformatics approaches that remove mouse stromal representation, thus permitting the quantification of human cancer transcripts only (Figure 3). This strategy has led to reconsidering the biological underpinnings of a poor-prognosis CRC transcriptional subtype (CMS4) that was initially assumed to include stem-like tumours featuring traits of cancer cell epithelial-mesenchymal transition^{47,48,49}. At some odds with this interpretation, species-specific expression analysis revealed that the transcript levels of CMS4 genes were mainly due to the copious presence of stromal cells rather than acquisition of a mesenchymal phenotype by cancer cells⁵⁰. This notion does not exclude that CMS4 also incorporates a more elusive subset of poorly differentiated cancer cells; indeed, mesenchymal markers have been found to be expressed in a fraction of CRC cell lines⁵¹ and in tumour epithelial cells of CRC patients⁵² and likely contribute, at least partially, to CMS4 assignment. However, the CMS4 identity seems to be driven more by cell populations belonging to the tumour reactive stroma than by epithelial cancer cells that have undergone widespread dedifferentiation.

In a complementary perspective, dissection of the human tumour stroma through subtractive analysis of matched pre-implantation tumours, PDXs, and normal tissue samples from the same patient led to the generation of a tumour microenvironmental gene expression signature for renal cell carcinoma (RCC)⁵³ (Figure 3). This signature had greater discriminatory power of histologic subtypes than a signature limited to cancer cell-specific genes, underscoring the importance of microenvironmental features in defining RCC histologies. The signature also allowed to designate a highly inflamed subtype that was enriched for cells of innate and adaptive immunity, associated with clinical signs of systemic inflammation, and predicted poor survival⁵³. Collectively, these results

underscore the potential of PDX-based species-specific transcriptional analyses to extract tumour classifiers with strong biological and clinical granularity.

Clinical considerations

Deciphering cancer-cell specific gene expression features that are not affected by stromal abundance may be useful to minimize the confounding variable of stromal-derived intratumoural heterogeneity in isolated biopsy samples, which may be randomly taken from the central tumour core (mainly composed of cancer cells) or the invasive front (with a higher representation of stromal cells) during routine diagnostic procedures⁵⁴. CRIS, a new CRC classification built only on PDX human cancer-cell transcripts⁵⁵, proved to be superior to whole-tissue gene expression signatures in reducing geographical selection bias⁵⁶. While signatures obtained from bulk tumours failed to assign samples from the same patient to the same subtype when classification scores were applied to gene expression data obtained from multiple CRC tumour regions, CRIS showed high accuracy in clustering tumour biopsies by patient-of-origin rather than region-of-origin⁵⁶. CRIS also yielded new subtypes that only partly overlapped with transcriptional classes developed from bulk tumours and identified patients at high risk of relapse or high probability of response to EGFR inhibitors⁵⁵. The clinical evaluation of signatures based on cancer cell-intrinsic transcripts, which are free from the confounding effects of stromal-derived intratumoural heterogeneity, is expected to deliver improved prognostic and predictive biomarkers for precision oncology decisions.

Response biomarker population studies

Response to targeted therapies occurs only in patients with genetically susceptible tumours and may be attenuated by various mechanisms of compensation⁵⁷. By capturing inter-individual tumour diversity on a population scale, PDXs represent appropriate pharmacogenomic platforms to identify molecular determinants that enrich for potential responders. Several studies have shown that PDXs reliably phenocopy the distribution of responses observed in patients and recapitulate clinically validated correlations between drug sensitivity and biomarker positivity. PDXs have also been instrumental to prospectively discovering response predictors for new and repurposed drugs in molecularly defined tumour subsets (Figure 4).

To enable adequate coverage of representative study populations, several cancer centres have shared their PDX collections in large, distributed repositories. These initiatives are meant not only to build ample PDX resources for the global scientific community, but also to formulate consensus guidelines for standard operating procedures and metadata harmonization⁵⁸. For some repositories, salient aspects of available PDX models (molecular characteristics, drug sensitivity, treatment history of donor patients) are described in the PDX Finder web portal (pdxfinder.org)⁵⁹ (Table 1).

Biomarker validation

PDX biobanks have been repeatedly utilized for systematic validation of response biomarkers that were initially identified through correlative analyses in patients. A pan-cancer high-throughput screen in 440 models from 16 cancer types supported several genotype-drug response associations already observed in the clinic⁶⁰, including *BRAF* and *NRAS* mutations as predictors of response and *de novo* resistance, respectively, to the BRAF inhibitor vemurafenib in melanoma^{61,62}, and *PIK3CA* mutations in the presence of a *PTEN* wild-type status as predictors of response to the PI3K inhibitor BYL719 in breast cancer⁶³ (Figure 4). Clinically established mechanisms of acquired resistance were also confirmed, namely, *BRAF* amplification and mutations in the MAPK genes *MAP2K1* (encoding MEK1) and *MAPK2* (encoding MEK2) in melanoma PDXs that had developed resistance to BRAF targeted therapy⁶⁴⁻⁶⁶ (Figure 4)

PDX pan-cancer repositories typically include the standard spectrum of common solid cancers, but the representation of individual tumour types is inevitably fragmented into relatively small collections. Some research groups have elected to pursue biomarker validation efforts using tumour-specific PDX resources as a means to draw more powered, tissue-oriented gene-drug association maps. CRC is a paradigmatic example of such an approach. In 2011, a study in 47 metastatic CRC PDXs confirmed the long-established clinical association between *KRAS* mutations in exon 2 and *de novo* resistance to the EGFR antibody cetuximab⁶⁷. When evaluating an additional cohort of 38 PDXs with a *KRAS* exon 2 wild-type status, the same study documented that metastatic CRC PDXs with *KRAS* mutations in exons 3 and 4 and *NRAS* mutations were also refractory to EGFR blockade⁶⁷. This observation would obtain clinical recognition only two years later, when results from a large trial yielded solid evidence that patients with tumours exhibiting “RAS extended” mutations treated with anti-EGFR therapy had shorter PFS and OS than patients with *KRAS/NRAS* wild-type tumours⁶⁸ (Figure 4).

In patients with metastatic CRC negative for RAS extended mutations, higher expression of the EGFR ligands amphiregulin and epiregulin correlates with a higher probability of response to anti-EGFR therapy^{69,70}, likely because CRC cells with ligand-activated EGFR experience a stronger dependency on the EGFR pathway. Accordingly, a survey in 125 RAS wild-type PDX models found a substantial enrichment of cetuximab-sensitive tumours among cases with elevated levels of amphiregulin and epiregulin⁷¹. High levels of EGFR pathway activity transcripts (epiregulin, EGFR, and the EGFR downstream amplifier *IRS2*) were also detected in the CRIS-C subgroup of the CRIS CRC cancer cell-intrinsic classifier, which was particularly enriched for cetuximab-responsive tumours⁵⁵. Notably, the abundance of epiregulin and amphiregulin decreased in tumour remnants from PDXs that regressed but did not disappear after prolonged treatment with cetuximab³⁶, suggesting that residual tumours that tolerate EGFR blockade are less reliant on EGFR signalling due to lower availability of EGFR agonists.

Biomarker discovery

Tumour-specific PDX collections have been successfully deployed for the nomination of novel determinants of response and resistance to clinically approved therapies. Differential gene expression analyses in a suite of 59 CRC PDXs enabled the identification of molecular profiles associated with sensitivity to some standard-of-care regimens. For example, 5-FU-responding xenografts tended to display transcriptional traits that recall those displayed by normal enterocytes and goblet cells⁷², whereas 5-FU-refractory models exhibited a less differentiated phenotype characterized by high expression of the transcription factors ASCL2 and MYC, two canonical markers of WNT signalling in colonic crypt stem cells⁷³ (Figure 4). In the case of bevacizumab, drug sensitivity was prevalent in tumours with higher expression of genes involved in ATP synthesis-coupled mitochondrial transport, while resistance correlated with higher expression of ERF⁷², a transcriptional repressor that is inactivated by the RAS-MAPK pathway⁷⁴ (Figure 4). Finally, response to EGFR blockade was more frequent in WNT-high, ASCL2/MYC-expressing tumours and was less pronounced in PDXs with elevated levels of the anti-apoptotic growth factor IGF2⁷² (Figure 4). The association between poor response to cetuximab and high IGF2 expression was also reported in an independent cohort of 125 metastatic CRC PDXs and retrospectively confirmed in patients⁷¹. Besides CRC, transcriptomic data from PDXs have been used to estimate predictive differences between chemosensitive and chemorefractory tumours in gastric cancer. Enrichment analyses of 31 PDXs that showed different sensitivity to the combination of 5-FU and oxaliplatin put forward proficient p53 signalling and increased metabolic processes as hallmarks of responsive cases (Figure 4), and high expression of mesenchymal genes and extracellular matrix receptors as markers of resistant cases⁷⁵. Whether all these predictive signatures can improve clinical decision making in CRC and gastric cancer remains to be determined.

Genetic determinants of resistance to EGFR inhibition in metastatic CRC PDXs without RAS extended mutations have been identified by gene candidate approaches or whole exome sequencing analyses of therapeutically annotated PDXs. Results from these investigations highlighted amplification of the *MET* and *ERBB2* genes (Figure 4) as well as mutations in *ERBB2*, *EGFR*, *FGFR1*, *PDGFRA*, and *MAP2K1* as potential mechanisms of primary resistance to cetuximab^{67,76-78}. Mutations in the ectodomain of EGFR, which prevent antibody binding, were also identified in PDXs from patients with acquired resistance to EGFR blockade⁷⁷. All these alterations proved to be clinically actionable, and when targeted by specific inhibitors sensitized tumours to EGFR blockade in PDX experiments⁷⁷.

In addition to being a standard-of-care therapy for patients with metastatic CRC, cetuximab is used for the treatment of recurrent or metastatic head-and-neck squamous cell carcinoma (HNSCC) in combination with platinum and 5-FU⁷⁹. Biomarker studies in HNSCC PDXs have provided evidence

that, similar to observations in CRC, tumours with high expression of EGFR ligands tend to be more sensitive to EGFR inhibition^{80,81} (Figure 4). This association was confirmed in platinum-resistant patients who had received single-agent panitumumab, another EGFR monoclonal antibody approved for metastatic CRC⁸². Moreover, some patients with platinum-resistant or cetuximab-resistant HNSCC respond to the combination of cetuximab and the CDK4/6 inhibitor palbociclib⁸³. Findings in PDXs suggest that this response is particularly pronounced in tumours displaying unrestrained activation of the CDK4/6 and cyclin D1 cell-cycle regulatory complex due to genomic inactivation of the CDK4/6 inhibitor p16INK4A or cyclin D1 overexpression⁸⁴ (Figure 4).

Irinotecan exerts its cytotoxic activity by trapping the target enzyme topoisomerase I on DNA, leading to stalled replication forks and DNA double-strand breaks (DSBs) during replication⁸⁵. A study in 40 PDXs has suggested that defects in the homologous recombination (HR) pathway – through which DSBs are sensed and repaired – may predict response to irinotecan in TNBC. BRCA1 and BRCA2, two key HR effectors, were mutationally inactivated or epigenetically silenced in the majority of irinotecan-sensitive TNBC PDXs⁸⁶(Figure 4). Some irinotecan-sensitive models also displayed high expression of SLFN11 (86), a putative DNA/RNA helicase that is recruited to the stressed replication forks and triggers lethal replication block in response to exogenously induced DNA damage^{87,88} (Figure 4). Conversely, SLFN11-low, irinotecan-resistant tumours had an improved response when irinotecan was combined with an inhibitor of ATR⁸⁶, another component of the DNA damage response machinery on which cells under replication stress become dependent when SLFN11 protein availability is limited⁸⁸.

The multi-kinase inhibitor lenvatinib is frequently used in patients with advanced hepatocellular carcinoma (HCC), but the overall response rate is only 24%⁸⁹. One potential mechanism of *de novo* resistance has been attributed to lenvatinib-induced feedback activation of EGFR, which appeared to be particularly pronounced in HCC cells with high EGFR expression (Figure 4). Accordingly, the combination of lenvatinib and the EGFR inhibitor gefitinib elicited marked tumour control in EGFR-high, but not in EGFR-low, HCC PDX models⁹⁰.

Altogether, population trials in PDXs have streamlined the identification of biomarkers of resistance to standard-of-care treatments and have brought to the fore alternative targets for refractory tumours. Remarkably, when testing investigational therapies, pharmacological experiments in PDXs were more stringent than those obtained in cultured cell lines. For example, while concomitant blockade of MEK and IGF1R exerted synergistic growth-inhibitory effects in a panel of cell lines from CRC, non-small cell lung cancer and pancreatic cancer, the same combination therapy was not superior to individual MEK inhibition in tumour type-matched PDXs⁶⁰. The higher specificity of results in PDXs is expected to de-prioritize false positive candidates that emerge from cell line-based drug screens, likely reducing attrition in drug development.

Clinical considerations

Results from PDX studies have shown that amplification of the *ERBB2* oncogene, which leads to overexpression and constitutive activation of the encoded receptor HER2, associates with poor response to anti-EGFR therapy in preclinical models of metastatic CRC^{67,77}. In confirmation of this finding, several retrospective studies have documented worse outcomes (shorter PFS and OS and lower objective response rates) in metastatic CRC patients with *ERBB2*-amplified tumours who received cetuximab alone or in combination with chemotherapy relative to patients with non-amplified tumours⁹¹⁻⁹³. PDX-based investigation has also been instrumental to define an optimal treatment regimen for cetuximab-resistant, *ERBB2*-amplified metastatic CRC. While single-agent therapy with the HER2 monoclonal antibody trastuzumab or the dual EGFR-HER2 tyrosine kinase inhibitor lapatinib failed to regress *ERBB2*-amplified PDX models, the combination of trastuzumab and lapatinib induced marked and durable tumour shrinkage⁹⁴. The mechanism underlying this synergy is ascribable to the ability of trastuzumab to counteract compensatory activation of the HER2 signalling partner HER3, which was triggered by prolonged treatment with lapatinib alone⁹⁴. When translated to heavily pre-treated patients with HER2-positive metastatic CRC, the combination therapy resulted in a 30% objective response rate (8/27) and a 74% disease control rate (20/27)⁹⁵. These data compare favourably with the rates achieved with other modalities approved for the advanced-line treatment of metastatic CRC, such as the multikinase small-molecule inhibitor regorafenib^{96,97} and chemotherapy with trifluridine plus tipiracil^{98,99}, and attest to the value of PDX-derived therapeutic results for predicting drug clinical efficacy.

Importantly, poor response in PDXs also anticipated suboptimal outcomes in patients. The pan-HER inhibitor neratinib was ineffective in metastatic CRC PDXs exhibiting *ERBB2* activating mutations⁷⁸. Likewise, no objective responses were seen after treatment with neratinib in 12 patients with CRC harbouring mutations in *ERBB2* or *ERBB3*¹⁰⁰. A survey of drug sensitivity in 32 CRC PDXs with *KRAS* mutations indicated limited efficacy of dual PI3K and MEK pathway blockade, with disease stabilization as best response¹⁰¹. In the same vein, no tumour regressions were observed in 21 patients with *KRAS* mutant metastatic CRC treated with a combination of selumetinib (a MEK inhibitor) and MK-2206 (which targets AKT, a downstream PI3K transducer)¹⁰².

The observation that lenvatinib-refractory HCC PDXs responded to the combination of lenvatinib and gefitinib⁹⁰ spurred the design of a clinical study in patients with unresectable HCC, whose tumours had progressed on lenvatinib monotherapy. Since results in PDXs showed that tumours with elevated EGFR protein levels were particularly susceptible to the combination of lenvatinib and gefitinib, only patients with EGFR-overexpressing HCCs were enrolled in the study. Data from an interim analysis of 12 patients suggest promising clinical activity of the dual therapy, with a 33% objective response rate observed so far⁹⁰.

Overall, the prominent examples of biomarker discovery and target validation presented above illustrate the contribution of PDX-based research to more informed patient stratification and delineate successful paths to the clinic of novel or repositioned therapies for patients with hard-to-treat tumours.

Future directions

PDXs grow and evolve in severely immunocompromised mice, and the human tumour stroma is substituted by murine components over consecutive passages. Hence, PDXs are intrinsically unfit to recapitulate heterotypic interactions between cancer cells, stromal cells, and immune cells. This limitation is compounded by the fact that in some cases cytokines and growth factors produced by mouse stromal cells do not cross-react with receptors expressed by human cancer cells, and *vice versa*¹⁰³; lack of a species-compatible stroma in PDXs makes it difficult to evaluate the contribution of the tumour microenvironment to therapeutic response and complicates the identification of pharmacodynamic biomarkers for drugs against microenvironmental targets, such as angiogenesis inhibitors.

The substitution of mouse stromal cells with their human counterparts is hard, if not impossible, to achieve with the current technologies. On the contrary, ongoing efforts are increasingly perfecting mouse humanization procedures for developing more holistic PDX models that contain human immune components^{104,105} (Figure 5). Severely immunodeficient mice can be engrafted with various types of human leukocytes, with each approach showing drawbacks. Peripheral blood mononuclear cells (PBMCs) can be easily collected from patients who donate their tumours for PDX generation, which avoids the immune reactions engendered by HLA mismatch; however, mature leukocytes from peripheral blood rapidly extinguish and cause xenogeneic graft-versus-host disease, limiting the time window of experimental testing to only a few weeks¹⁰⁶⁻¹⁰⁸. CD34-positive human haematopoietic stem cells give rise to various lineages of human blood cells throughout the animal's lifespan¹⁰⁹, but they are hardly obtainable from debilitated cancer patients. Human haematopoiesis in host mice can be supported by the introduction of mesenchymal stromal cells and by the replacement of endogenous murine cytokines with their human equivalents¹¹⁰⁻¹¹², which optimizes mouse humanization but also complicates procedures. Based on these considerations, it is likely that humanized PDX models will be increasingly used for selected proof-of-concept studies, for example to investigate the impact of immunotherapy on the function and localization of immune effector cells or to detect immunologically and clinically relevant tumour antigens. However, it is difficult to envision a routine deployment of such models to identify patient- and tumour-specific biomarkers of response to immunotherapy on a population scale.

PDX experimentation is notoriously expensive, labour-intensive and time-consuming. Hence, initial attempts have been undertaken that leverage the logistic advantages of scale, cost and time offered by lower model organisms – in particular, zebrafish – for phenotypic testing of drug

response^{113,114} (Figure 5). In their early larval development, zebrafish do not have a competent adaptive immune system, thus representing good recipients for the xenotransplantation of human tissues. Zebrafish larvae PDXs from patients with CRC who did not relapse on adjuvant therapy with 5-FU and oxaliplatin showed a higher number of apoptotic cells after treatment with the same chemotherapeutic regimen than PDXs from patients with clinical evidence of early recurrence¹¹⁵. Moreover, in consonance with clinical observations, zebrafish PDX models bearing *KRAS* mutant tumours did not respond to cetuximab¹¹⁵. Also this system, however, has limitations. After the initial period of functional immaturity during the larval stage, adaptive immunity rapidly ensues and leads to rejection of engrafted human cells, thus reducing the timing of tumour growth assessment to 1-2 weeks only; further, only very small numbers of cancer cells can be transplanted due to the minute dimensions of zebrafish larvae, which renders tumour visualization difficult. To overcome these hurdles, an immune-deficient model of adult zebrafish has been developed that enables the long-term engraftment of larger amounts of human cancer cells, including fragments of patient tumours¹¹⁶. By utilizing this model, the combination of the PARP inhibitor olaparib and the genotoxic agent temozolomide was identified as an effective therapy for rhabdomyosarcoma¹¹⁶ and is now being tested in a phase I clinical trial in adult patients with recurrent/metastatic Ewing's sarcoma or rhabdomyosarcoma following failure of prior chemotherapy (NCT01858168)¹¹⁷. The field is still in its infancy, and large-scale comparative studies are needed to define the extent to which genetic and transcriptional heterogeneity is maintained in zebrafish xenotransplants compared with original patients' tumours. However, proof-of-concept clinical prediction efforts appear to deliver encouraging results.

Humanized PDXs and zebrafish have the merit of reflecting organismal complexity, but their throughput remains low. Moreover, xenograft procedures are subject to application of the 3R's principles (reduction, refinement and replacement), which legitimately impose some control over the number of laboratory animals to be utilized for experimental purposes. To address these limitations, platforms for high-content *ex vivo* drug testing have been created using patient-derived or PDX-derived short-term explants from different cancer types (Figure 5). Results from these cultures confirmed known mechanisms of drug sensitivity and resistance (for example, sensitivity to PARP blockade in breast cancer models with somatic *BRCA1* promoter methylation or germline *BRCA1* mutations, and resistance in models with genetic loss of non-homologous end-joining genes)¹¹⁸; documented genetic and non-genetic mechanisms of acquired resistance to targeted therapies (for example, adaptive upregulation of SRC kinase activity after ALK inhibition in ALK-translocated lung tumours)¹¹⁹; and identified genetic predictors useful for drug repurposing (for example, EGFR mutations and amplification as predictors of response to the Bruton kinase inhibitor ibrutinib in glioma)¹²⁰.

Although short-term explants are expected to preserve the molecular characteristics of parental tumours, they rapidly exhaust their proliferative capacity. In recent years, three-dimensional *in vitro* organotypic cultures have been developed that overall maintain the phenotype, genetic diversity and transcriptional features of original tumour samples and can be passaged for extended periods¹²¹ (Figure 5). Similar to PDXs, tumour organoids have proven useful to explore the genetic and functional underpinnings of intratumour heterogeneity, including the hierarchy and plasticity of cancer stem cells¹²², the trajectories of cancer phylogenetic evolution¹²³ and the patterns of signalling dynamics and transcriptional outputs at the single-cell level^{124,125}. Initial evidence suggests that tumour organoids can also trigger antigen-specific expansion of tumour-reactive cytotoxic T cells and antibody-dependent tumour cytotoxicity when cultured with autologous PBMCs¹²⁶ or as cohesive units incorporating en bloc the tumour epithelium and its endogenous immune repertoire¹²⁷. Drug sensitivity profiles in organoids have shown initial signs of consistency with patient response, with concordant results for several cytotoxic agents in gastrointestinal tumours^{128,129}, and have been used to guide effective therapeutic decisions in a donor patient with TNBC¹³⁰. However, a recent prospective study in which CRC avatar organoids were used to inform experimental treatments in donor patients suggested that organoids might not be universally predictive, as strong pharmacological effects observed in organoids did not translate into durable clinical benefit in patients¹³¹. This discrepancy advocates the need for more refined metrics and readouts to assess cell viability in organoids and suggests that, at least for some agents, *ex vivo* pharmacology highly differs from compound activity *in vivo*.

Ultimately, we envision a scenario of increasing complexity where the burden inherent in PDX-based experimentation will be reduced by preliminary drug screens using less laborious formats, such as those offered by organoids and zebrafish, followed by validation of prioritized hits in mice. This stepwise approach will likely facilitate the use of patient-derived models also for investigating clinically actionable vulnerabilities that have been traditionally studied using conventional cell lines, such as those related to cancer metabolism and epigenetic modifications.

Conclusions

PDX models have proven valuable to explore many different facets of precision oncology in the preclinical space. The use of PDXs to study the clonal dynamics of tumour evolution has contributed substantial knowledge to understanding how genetic and adaptive responses to drug pressure limit therapeutic efficacy over the course of treatment. PDX collections reflecting the molecular diversity of a particular cancer type have been instrumental to nominating biomarkers that predict sensitivity or resistance to a given therapy, thus improving clinical decision making and rational patient stratification. The identification of molecularly enriched responder populations has also spurred

clinical translation hypotheses that, in turn, have led to the discovery of new drug targets and the design of new therapies.

The growing appreciation that tumours are dependent not only on mutant genes but also on more elusive non-genetic factors underscores the importance of making the representation of cancer types wider, and their molecular characterization deeper, in PDX repositories. We surmise that the refinement and expansion of *ex vivo* and *in vivo* preclinical models, coupled with the increasing potential of functional perturbation approaches, will provide unprecedented opportunities to systematically map cancer liabilities and find effective ways to intercept the identified targets first in laboratory experiments, and then in patients.

KEY POINTS

- Owing to the selection bottleneck imposed by tumour engraftment and the evolutionary trajectories experienced by cancer cells along passaging, PDXs can be used to investigate tumour clonal composition and competition during spontaneous tumour progression and under drug pressure.
- Studies in PDXs at maximal response to a given therapy have provided insight into lineage-specific phenotypic adaptations, which underlie the acquisition of drug tolerance and are responsible for sustaining residual disease.
- The substitution of the human stroma by murine stroma after tumour implantation has enabled the identification of cancer cell-intrinsic and stroma-centred signatures with predictive and prognostic significance.
- Large collections of PDXs have contributed to the discovery and validation of novel response biomarkers and have aided the design of new therapeutic options, some of which have entered the clinic.
- Next-generation models with higher tissue complexity (humanized mice) or easier manageability (lower organisms, *ex vivo* cultures) are being developed that complement conventional PDX models.

ACKNOWLEDGEMENTS

We thank our friends and colleagues of the Laboratory of Translational Cancer Medicine at the Candiolo Cancer Institute for comments and suggestions. Work in the authors' laboratory is supported by AIRC, Associazione Italiana per la Ricerca sul Cancro, Investigator Grant 22802; AIRC 5x1000 grant 21091 ; AIRC/CRUK/FC AECC Accelerator Award 22795; European Union's H2020 grant agreement no. 754923 COLOSSUS; and Fondazione Piemontese per la Ricerca sul Cancro-ONLUS, 5x1000 Ministero della Salute 2016. L. T. is a member of the EurOPDX consortium. All figures were initially created with Biorender.com.

COMPETING INTERESTS

L.T. has received research grants from Menarini, Merck KGaA, Merus, Pfizer, Servier and Symphogen. The remaining authors declare no competing interests.

LEGENDS TO FIGURES

Figure 1. **PDXs as dynamic tools to trace cancer clonal evolution.** Cancers display extensive intratumour genetic diversity, with founding clones giving rise to genetically heterogeneous subclones endowed with different biological fitness, spatial distribution and evolutionary trajectories. Clonal competition dynamically shapes the genomic architecture of tumours during cancer progression and under therapeutic pressure. When tumour fragments are implanted in mice to generate PDXs, there is an initial geographical bias related to sampling, followed by a strong selection bottleneck due to successful engraftment of only a fraction of cancer cells. Serial PDX passaging also contributes to clonal evolution, which can be further exacerbated by drug treatments in recipient mice. Thus, PDXs can be exploited to investigate how the clonal fitness landscape and the ensuing phenotypic divergence of individual tumours are influenced by space, time and drug insults under controlled experimental conditions.

Figure 2. **Studying phenotypic rewiring in drug-tolerant persisters using PDXs.** Research in PDXs has shown that residual tumours at maximal response to a successful therapy are made of drug-tolerant persister cells that have (re)acquired ancestral phenotypes physiologically expressed during embryogenesis or tissue regeneration. *BRAF* mutant melanoma PDXs exposed to dual BRAF/MEK blockade initially engaged a “starvation”-like transcriptional programme, which was followed by differentiation into pigment-producing cells or dedifferentiation toward either an invasive or a neural crest stem cell state³⁰. Phenotypic transition to the neural crest stem cell state was driven by retinoic X receptor- γ and was accompanied by increased FAK signalling, which was caused by autocrine production of glial-derived neurotrophic factor^{30,31}. Accordingly, concurrent blockade of BRAF/MEK and FAK reduced the emergence of residual cells with a neural crest stem cell state, minimized residual disease, and delayed the development of resistance³¹. In metastatic CRC, tumour remnants surviving prolonged exposure to the EGFR antibody cetuximab exhibited reduced activity of the transcriptional co-activator YAP. In turn, YAP inhibition led to increased expression of transcription factors that specify the secretory fate of intestinal progenitors (such as ATOH1) and of markers of Paneth cell terminal differentiation (such as DEFA5), together with compensatory upregulation of HER2 and HER3 (36). The Paneth-like cells that compose CRC residual tumours were reminiscent of slowly cycling secretory precursors identified in the normal mouse intestine, which are committed to differentiate into Paneth cells when EGFR signalling is low³³⁻³⁵. Conversely, the cells of treatment-naïve CRC tumours resembled actively dividing intestinal stem cells that, during post-injury intestinal regeneration, reduce their differentiation capacity towards Paneth cells and contribute to tissue reconstitution in an EGFR- and YAP-dependent manner¹³³. The phenotype of CRC PDXs that tolerated treatment with 5-FU and irinotecan echoed that of diapause, an interval of

suspended development that may occur in blastocysts before implantation and is characterized by diminished mTOR signalling and upregulation of autophagy genes³⁷⁻⁴⁰. BRAFi, BRAF inhibitor; EGFRi, EGFR inhibitor; FAKi, FAK inhibitor; GDNF, glial-derived neurotrophic factor; NCSC, neural crest stem cells; RXR γ , retinoic X receptor- γ ; SMC, starved-like melanoma cells.

Figure 3. Deciphering the contribution of cancer cells versus stromal cells for tumour molecular subtyping and prognosis using PDXs. In human tumours engrafted in mice, the human tumour stroma is rapidly substituted by murine components. Therefore, PDXs are chimeras made of human cancer cells and murine stromal cells, and gene expression profiles from bulk xenografts are a mixture of human and murine transcripts. Using subtractive bioinformatic approaches to remove mouse RNA and extract human-only (i.e., cancer cell-only) transcripts from PDX microarray data, consensus molecular subtypes identified in CRC bulk tumours were still detectable in PDX tissues with the exception of subtype 4, which was almost completely lost in PDXs. This analysis led to a reconsideration of the molecular features of subtype 4, which proved to be mostly driven by stromal abundance rather than cancer cell mesenchymal dedifferentiation as originally assumed⁵⁰. Similarly, subtractive analyses of matched parental tumours, PDXs and normal tissues from the same patient were performed in RCC samples; by doing so, a human stromal subtype enriched for innate and adaptive immune cells was established, which correlated with systemic inflammatory manifestations and predicted poor survival⁵³. CMS, consensus molecular subtype.

Figure 4. PDXs as platforms for biomarker validation and discovery. Population studies in PDXs have validated clinical correlations between biomarker positivity and response (green) or resistance (red) to several targeted therapies in different cancer types. New predictive determinants have also emerged from discovery studies with PDXs, and some of them have been confirmed clinically. When druggable, resistance biomarkers (for example, HER2 in cetuximab-resistant CRC and EGFR in lenvatinib-resistant HCC) have proven to be effective therapeutic targets in PDXs, setting the stage for biomarker-driven clinical trials. AREG, amphiregulin; EREG, epiregulin. FOLFOX, 5-FU, leucovorin and oxaliplatin.

Figure 5. Emerging patient-derived cancer models. The features of humanized mouse models, zebrafish and patient-derived cultures are visualized and benchmarked against a series of parameters. Humanized PDX models recapitulate the spectrum of human genotypic and phenotypic traits more comprehensively than any other experimental system but at the same time have important drawbacks related to HLA compatibility between donor tumours and donor immune cells, cytokine species-specificity for adequate human haematopoiesis in mice, and scalability. Zebrafish and patient-derived cell cultures are more prone to high-throughput procedures, with cultures having the

further advantage of avoiding animal experimentation. However, both models remain in their infancy in terms of biological conclusiveness and clinical generalizability of pharmacological results. We surmise that the availability of model systems characterized by increasing organismal complexity will facilitate the implementation of stepwise drug development pipelines, whereby the prioritization of hits shortlisted from initial screens in simpler models culminates in ultimate go/no-go decisions based on therapeutic outcomes in PDXs and humanized mice.

REFERENCES

1. Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. *Cell* **153**, 17–37 (2013).
2. Vogelstein, B. et al. Cancer genome landscapes. *Science* **339**, 1546–1558 (2013).
3. Hahn, W. C. et al. An expanded universe of cancer targets. *Cell* **184**, 1142–1155 (2021).
4. McCoach, C. E. & Bivona, T. G. Engineering multidimensional evolutionary forces to combat cancer. *Cancer Discov.* **9**, 587–604 (2019).
5. Marine, J.-C., Dawson, S.-J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. *Nat. Rev. Cancer* **20**, 743–756 (2020).
6. Garraway, L. A. Genomics-driven oncology: framework for an emerging paradigm. *J. Clin. Oncol.* **31**, 1806–1814 (2013).
7. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature* **505**, 495–501 (2014).
8. Byrne, A. T. et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. *Nat. Rev. Cancer* **17**, 254–268 (2017).
9. Stripecke, R. et al. Innovations, challenges, and minimal information for standardization of humanized mice. *EMBO Mol. Med.* **12**, e8662 (2020).
10. De Palma, M., Biziato, D. & Petrova, T. V. Microenvironmental regulation of tumour angiogenesis. *Nat. Rev. Cancer* **17**, 457–474 (2017).
11. Bailey, C. et al. Tracking cancer evolution through the disease course. *Cancer Discov.* **11**, 916–932 (2021).
12. Aparicio, S., Hidalgo, M. & Kung, A. L. Examining the utility of patient-derived xenograft mouse models. *Nat. Rev. Cancer* **15**, 311–316 (2015).
13. Avolio, M. & Trusolino, L. Rational treatment of metastatic colorectal cancer: A reverse tale of men, mice, and culture dishes. *Cancer Discov.* **11**, 1644–1660 (2021).
14. Ben-David, U. et al. Patient-derived xenografts undergo mouse-specific tumor evolution. *Nat. Genet.* **49**, 1567–1575 (2017).
15. Woo, X. Y. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. *Nat. Genet.* **53**, 86–99 (2021).
16. Hoge, A. C. H. et al. DNA-based copy number analysis confirms genomic evolution of PDX models. *N.P.J. Precis. Oncol.* **6**, 30 (2022).
17. Sun, H. et al. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. *Nat. Commun.* **12**, 5086 (2021).
18. Schmitt, M. W., Loeb, L. A. & Salk, J. J. The influence of subclonal resistance mutations on targeted cancer therapy. *Nat. Rev. Clin. Oncol.* **13**, 335–347 (2016).

19. Izumchenko, E. et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. *Ann. Oncol.* **28**, 2595–2605 (2017).
20. Hidalgo, M. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. *Mol. Cancer Ther.* **10**, 1311–1316 (2011).
21. Eirew, P. et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. *Nature* **518**, 422–426 (2015).
22. Salehi, S. et al. Clonal fitness inferred from time-series modelling of single-cell cancer genomes. *Nature* **595**, 585–590 (2021).
23. Dang, H. X. et al. The clonal evolution of metastatic colorectal cancer. *Sci. Adv.* **6**, eaay9691 (2020).
24. Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. *Science* **339**, 543–548 (2013).
25. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell* **141**, 69–80 (2010).
26. Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. *Nat. Med.* **22**, 262–269 (2016).
27. Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. *Nature* **596**, 576–582 (2021).
28. Fakhri, M. G. et al. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. *Clin. Cancer Res.* **16**, 3786–3794 (2010).
29. Meng, Y. et al. Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer. *Ann. Palliat. Med.* **10**, 11255–11264 (2021).
30. Cleary, J. M. et al. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. *Invest. New Drugs* **32**, 937–945 (2014).
31. Vlahovic, G. et al. A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. *Invest. New Drugs* **32**, 976–984 (2014).
32. Rambow, F. et al. Toward Minimal Residual Disease-Directed Therapy in Melanoma. *Cell* **174**, 843-855.e19 (2018).
33. Marin-Bejar, O. et al. Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. *Cancer Cell* **39**, 1135-1149.e8 (2021).
34. Vendramin, R. et al. Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma. *J. Exp. Med.* **218**, (2021).

35. Buczacki, S. J. A. et al. Intestinal label-retaining cells are secretory precursors expressing Lgr5. *Nature* **495**, 65–69 (2013).
36. Basak, O. et al. Induced Quiescence of Lgr5+ Stem Cells in Intestinal Organoids Enables Differentiation of Hormone-Producing Enteroendocrine Cells. *Cell Stem Cell* **20**, 177-190.e4 (2017).
37. Barriga, F. M. et al. Mex3a marks a slowly dividing subpopulation of Lgr5+ intestinal stem cells. *Cell Stem Cell* **20**, 801-816.e7 (2017).
38. Lupo, B. et al. Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. *Sci. Transl. Med.* **12**, (2020).
39. Rehman, S. K. et al. Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy. *Cell* **184**, 226-242.e21 (2021).
8. Fenelon, J. C., Banerjee, A. & Murphy, B. D. Embryonic diapause: development on hold. *Int. J. Dev. Biol.* **58**, 163–174 (2014).
9. Bulut-Karslioglu, A. et al. Inhibition of mTOR induces a paused pluripotent state. *Nature* **540**, 119–123 (2016).
10. Dhimolea, E. et al. An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. *Cancer Cell* **39**, 240-256.e11 (2021).
11. US National Library of Medicine. *ClinicalTrials.gov* <https://clinicaltrials.gov/ct2/show/NCT04109456> (2021).
12. US National Library of Medicine. *ClinicalTrials.gov* <https://clinicaltrials.gov/ct2/show/NCT04720417> (2022).
13. Deeken, J. F. et al. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies. *Cancer* **121**, 1645–1653 (2015).
14. Hill, A. G. et al. Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. *Clin. Cancer Res.* **24**, 2276–2284 (2018).
15. Mahalingam, D. et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. *Autophagy* **10**, 1403–1414 (2014).
16. Orlov, S. V. et al. Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab. *Case Rep. Oncol.* **13**, 985–989 (2020).
17. De Sousa E Melo, F. et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. *Nat. Med.* **19**, 614–618 (2013).

18. Sadanandam, A. et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. *Nat. Med.* **19**, 619–625 (2013).
19. Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. *Nat. Med.* **21**, 1350–1356 (2015).
20. Isella, C. et al. Stromal contribution to the colorectal cancer transcriptome. *Nat. Genet.* **47**, 312–319 (2015).
21. Medico, E. et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. *Nat. Commun.* **6**, 7002 (2015).
22. Trinh, A. et al. Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry. *Clin. Cancer Res.* **23**, 387–398 (2017).
23. Wang, T. et al. An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors. *Cancer Discov.* **8**, 1142–1155 (2018).
24. Dunne, P. D. et al. Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer. *Clin. Cancer Res.* **22**, 4095–4104 (2016).
25. Isella, C. et al. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. *Nat. Commun.* **8**, 15107 (2017).
26. Dunne, P. D. et al. Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification. *Nat. Commun.* **8**, 15657 (2017).
27. Trusolino, L. & Bertotti, A. Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation. *Cancer Discov.* **2**, 876–880 (2012).
28. Meehan, T. F. et al. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. *Cancer Res.* **77**, e62–e66 (2017).
29. Conte, N. et al. PDX Finder: A portal for patient-derived tumor xenograft model discovery. *Nucleic Acids Res.* **47**, D1073–D1079 (2019).
30. Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. *Nat. Med.* **21**, 1318–1325 (2015).
31. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N. Engl. J. Med.* **364**, 2507–2516 (2011).
32. Trunzer, K. et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. *J. Clin. Oncol.* **31**, 1767–1774 (2013).
33. Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)K α inhibitor. *Nature* **518**, 240–244 (2015).

34. Shi, H. et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. *Nat. Commun.* **3**, 724 (2012).
35. Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. *Cancer Discov.* **4**, 80–93 (2014).
36. Rizos, H. et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. *Clin. Cancer Res.* **20**, 1965–1977 (2014).
37. Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. *Cancer Discov.* **1**, 508–523 (2011).
38. Douillard, J.-Y. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N. Engl. J. Med.* **369**, 1023–1034 (2013).
39. Khambata-Ford, S. et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. *J. Clin. Oncol.* **25**, 3230–3237 (2007).
40. Jacobs, B. et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. *J. Clin. Oncol.* **27**, 5068–5074 (2009).
41. Zanella, E. R. et al. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. *Sci. Transl. Med.* **7**, 272ra12 (2015).
42. Schütte, M. et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. *Nat. Commun.* **8**, 14262 (2017).
43. Schuijers, J. et al. Ascl2 acts as an R-spondin/Wnt-responsive switch to control stemness in intestinal crypts. *Cell Stem Cell* **16**, 158–170 (2015).
44. von Kriegsheim, A. et al. Cell fate decisions are specified by the dynamic ERK interactome. *Nat. Cell Biol.* **11**, 1458–1464 (2009).
45. Na, D. et al. Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts. *Nat. Commun.* **12**, 4840 (2021).
46. Bardelli, A. et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. *Cancer Discov.* **3**, 658–673 (2013).
47. Bertotti, A. et al. The genomic landscape of response to EGFR blockade in colorectal cancer. *Nature* **526**, 263–267 (2015).
48. Kavuri, S. M. et al. HER2 activating mutations are targets for colorectal cancer treatment. *Cancer Discov.* **5**, 832–841 (2015).
49. Vermorken, J. B. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N. Engl. J. Med.* **359**, 1116–1127 (2008).

50. Klinghammer, K. et al. Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer. *Int. J. Cancer* **141**, 1215–1221 (2017).
51. Huang, C. et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. *Cancer Cell* **39**, 361-379.e16 (2021).
52. Siano, M. et al. Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. *Oral Oncol.* **82**, 144–151 (2018).
53. Adkins, D. et al. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. *Lancet Oncol.* **20**, 1295–1305 (2019).
54. Karamboulas, C. et al. Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma. *Cell Rep.* **25**, 1318-1331.e4 (2018).
55. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. *Nat. Rev. Cancer* **6**, 789–802 (2006).
56. Coussy, F. et al. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. *Sci. Transl. Med.* **12**, (2020).
57. Zoppoli, G. et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 15030-15035 (2012).
58. Murai, J. et al. SLFN11 blocks stressed replication forks independently of ATR. *Mol. Cell* **69**, 371-384.e6 (2018).
59. Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet* **391**, 1163–1173 (2018).
60. Jin, H. et al. EGFR activation limits the response of liver cancer to lenvatinib. *Nature* **595**, 730–734 (2021).
61. Yonesaka, K. et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. *Sci. Transl. Med.* **3**, 99ra86 (2011).
62. Martin, V. et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. *Br. J. Cancer* **108**, 668–675 (2013).
63. Sartore-Bianchi, A. et al. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. *Oncologist* **24**, 1395–1402 (2019).
64. Leto, S. M. et al. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas. *Clin. Cancer Res.* **21**, 5519–5531 (2015).

65. Sartore-Bianchi, A. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. *Lancet Oncol.* **17**, 738–746 (2016).
66. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* **381**, 303–312 (2013).
67. Li, J. et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* **16**, 619–629 (2015).
68. Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N. Engl. J. Med.* **372**, 1909–1919 (2015).
69. Xu, J. et al. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients with Previously Treated Metastatic Colorectal Cancer: The TERRA Study. *J. Clin. Oncol.* **36**, 350–358 (2018).
70. Hyman, D. M. et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. *Nature* **554**, 189–194 (2018).
71. Migliardi, G. et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. *Clin. Cancer Res.* **18**, 2515–2525 (2012).
72. Do, K. et al. Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. *Invest. New Drugs* **33**, 720–728 (2015).
103. Mestas, J. & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. *J. Immunol.* **172**, 2731–2738 (2004).
104. Rongvaux, A. et al. Human hemato-lymphoid system mice: current use and future potential for medicine. *Annu. Rev. Immunol.* **31**, 635–674 (2013).
105. Zitvogel, L., Pitt, J. M., Daillère, R., Smyth, M. J. & Kroemer, G. Mouse models in oncoimmunology. *Nat. Rev. Cancer* **16**, 759–773 (2016).
106. Guichelaar, T. et al. Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells. *Clin. Cancer Res.* **19**, 1467–1475 (2013).
107. King, M. A. et al. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. *Clin. Exp. Immunol.* **157**, 104–118 (2009).

108. Holzapfel, B. M., Wagner, F., Thibaudeau, L., Levesque, J. P. & Huttmacher, D. W. Concise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineering. *Stem Cells* **33**, 1696–1704 (2015).
109. Drake, A. C., Chen, Q. & Chen, J. Engineering humanized mice for improved hematopoietic reconstitution. *Cell. Mol. Immunol.* **9**, 215–224 (2012).
110. Ito, R. et al. Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. *J. Immunol.* **191**, 2890–2899 (2013).
111. Billerbeck, E. et al. Development of human CD4⁺FoxP3⁺ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2R γ null humanized mice. *Blood* **117**, 3076–3086 (2011).
112. Rongvaux, A. et al. Development and function of human innate immune cells in a humanized mouse model. *Nat. Biotechnol.* **32**, 364–372 (2014).
113. Cagan, R. L., Zon, L. I. & White, R. M. Modeling Cancer with Flies and Fish. *Dev. Cell* **49**, 317–324 (2019).
114. Fazio, M., Ablain, J., Chuan, Y., Langenau, D. M. & Zon, L. I. Zebrafish patient avatars in cancer biology and precision cancer therapy. *Nat. Rev. Cancer* **20**, 263–273 (2020).
115. Fior, R. et al. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. *Proc Natl Acad Sci USA* **114**, E8234–E8243 (2017).
116. Yan, C. et al. Visualizing engrafted human cancer and therapy responses in immunodeficient zebrafish. *Cell* **177**, 1903-1914.e14 (2019).
117. US National Library of Medicine. *ClinicalTrials.gov* <https://clinicaltrials.gov/ct2/showNCT01858168> (2021).
118. Bruna, A. et al. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. *Cell* **167**, 260-274.e22 (2016).
119. Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. *Science* **346**, 1480–1486 (2014).
120. Lee, J.-K. et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. *Nat. Genet.* **50**, 1399–1411 (2018).
121. Veninga, V. & Voest, E. E. Tumor organoids: Opportunities and challenges to guide precision medicine. *Cancer Cell* **39**, 1190–1201 (2021).
122. Shimokawa, M. et al. Visualization and targeting of LGR5⁺ human colon cancer stem cells. *Nature* **545**, 187–192 (2017).
123. Roerink, S. F. et al. Intra-tumour diversification in colorectal cancer at the single-cell level. *Nature* **556**, 457–462 (2018).

124. Ponsioen, B. et al. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling. *Nat. Cell Biol.* **23**, 377–390 (2021).
125. LeBlanc, V. G. et al. Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity. *Cancer Cell* **40**, 379-392 (2022).
126. Dijkstra, K. K. et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. *Cell* **174**, 1586-1598 (2018).
127. Neal, J. T. et al. Organoid modeling of the tumor immune microenvironment. *Cell* **175**, 1972-1988 (2018).
128. Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. *Science* **359**, 920–926 (2018).
129. Ooft, S. N. et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. *Sci. Transl. Med.* **11**, (2019).
130. Guillen, K. P. et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. *Nat. Cancer* **3**, 232-250 (2022).
131. Ooft, S. N. et al. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses. *ESMO Open* **6**, 100103 (2021).
132. Dudová, Z. et al. The EurOPDX Data Portal: an open platform for patient-derived cancer xenograft data sharing and visualization. *BMC Genomics* **23**, 156 (2022).
133. Gregorieff, A., Liu, Y., Inanlou, M. R., Khomchuk, Y. & Wrana, J. L. Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer. *Nature* **526**, 715-718 (2015).




Fig.1

Melanoma Colorectal cancer








Fig.2




Fig.3




Fig.4




Fig.5

Table 1. Facts and figures of international PDX repositories

Repository	Contributing institution (number of models)^a	Tumour types (number of models)^b	Sites (number of models)	Molecular annotations (number of models)	Therapeutic annotations (number of models)
EurOPDX	IRCC (715) VHIO (122) UOC (59) LIH (40) TRACE (31) Curie (16) UOM (12) UMCG (8) NKI (7)	Digestive system (842) Breast (86) Nervous system (40) Reproductive system (13) Skin (8)	Primary (413) Metastasis (584) Undefined (13)	SNVs/indels (653) CNA (505) Gene expression (266)	283
JAX PDX	JAX (426)	Digestive system (100) Thoracic cavity (77) Haematopoietic/lymphoid tissues (47) Breast (44) Connective/soft tissues (38)	Primary (229) Metastasis (145) Undefined (52)	SNVs/indels (353) CNA (300) Gene expression (379)	90
PDXnet	MD Anderson (316) Winstar-MD Anderson-Penn (256) WUSTL (119) BCM (51)	Digestive system (225) Thoracic cavity (129) Skin (119) Breast (102) Connective/soft tissues (11)	Primary (263) Metastasis (452) Undefined (27/	SNVs/indels (534) CNA (534) Gene expression (534)	0
PPTC	PPTC (261)	Haematopoietic/lymphoid tissues (90) Nervous system (76) Connective/soft tissues (62) Endocrine system (2) Digestive system (2)	Primary (164) Undefined (97)	SNVs/indels (240) CNA (252) Gene expression (252)	0

Others	DFCI-CPDM (731) CRL (540) PDMR-NCI 378 PMLB 284 SJCRH 170	Digestive system (652) Haematopoietic/lymphoid tissues (259) Thoracic cavity (184) Connective/soft tissues (157) Reproductive system (154)	Primary (763) Metastasis (435) Undefined (905)	SNVs/indels (966) CNA (529) Gene expression (468)	0
--------	---	--	--	---	---

Data refer to information available in the PDX Finder web portal⁵⁹ as of May 15th, 2022. Models available at EurOPDX can also be browsed in the EurOPDX Data Portal (<https://dataportal.euopdx.eu/>)¹³². Contributing institutions: BCM, Baylor College of Medicine, Houston, TX, USA; CRL, Charles River Laboratories, Bar Harbor, ME, USA; Curie, Institut Curie, Paris, FR; DFCI-CPDM, Dana-Farber Cancer Institute – Center for Patient-Derived Models, Boston, MA, USA; IRCC, Candiolo Cancer Institute, University of Turin, Turin, IT; JAX, The Jackson Laboratory, Farmington, CT, USA; LIH, Luxembourg Institute of Health, Esch-sur-Alzette, LU; MD Anderson, MD Anderson Cancer Center, Houston, TX, USA; NKI, Netherlands Cancer Institute, Amsterdam, NL; PDMR-NCI, Patient-Derived Models Repository – National Cancer Institute, Bethesda, MD, USA; PMLB, Princess Margaret Cancer Centre Living Biobank, Toronto, CA; PPTC, Pediatric Preclinical Tumor Consortium, Nationwide Children's Hospital, Columbus, OH, USA; SJCRH, St Jude Children's Research Hospital, Memphis, TN, USA; TRACE, TRACE-PDTP platform, Catholic University, Leuven, BE; UMCG, University Medical Center, Groningen, NL; UOC, University of Cambridge, Cambridge, UK; UOM, University of Manchester, Manchester, UK; VHIO, Vall d'Hebron Institute of Oncology, Barcelona, ES; WUSTL, Washington University, St. Louis, MO, USA. CNA, copy number alteration; SNV, single nucleotide variation. ^aFor each repository, tumour types include those that form the top 5 largest collections. ^bFor effective parsing of the PDX Finder database, tumours are catalogued based on anatomical location.